Ergomed establishes new revenue stream, adds specialist pharmacoepidemiology services

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Doucefleur)
(Image: Getty/Doucefleur)
Ergomed has added specialist pharmacoepidemiology services at its PrimeVigilance subsidiary to support increasing demand from regulators globally, says CEO.

“The primary driver for the need of pharmacoepidemiology is increased enforcement by regulators worldwide to generate pharmacovigilance real-world evidence,”​ Dr. Jan Petracek, COO and CEO of PrimeVigilance.

“This is closely linked with pharmacovigilance planning and risk management, which have now entered in a new phase of maturity,”​ he told us.

“As a result, the vast majority of new products, and almost always when an important safety concern is identified, post-authorization safety and/or efficacy studies are requested by the regulator.”

Following the acquisition, PrimeVigilance, Ergomed’s pharmacovigilance subsidiary, will now be able to provide a full service in these areas.

The company also has hired Dr. Michael Forstner. Dr Forstner’s role will be the Head of Pharmacoepidemiology and Risk Management, establishing a new revenue stream for Ergomed,”​ said Petracek.

In October last year​, Ergomed bolstered its orphan drug development services with the acquisition of PSR Group BV in a deal that was worth up to $6.69m.

Related topics: Clinical Development

Related news

Follow us

Products

View more

Webinars